Hyderabad, Jun 28 (UNI): Dr. Reddy’s Laboratories Limited, on Monday announced the commercial launch of 2-deoxy-D-glucose (2-DG), anti-Covid drug.
With Maximum Retail Price (MRP) of each sachet fixed at Rs 990, the drug will be supplied to major Governments as well as private hospitals across the country, Hyderabad based Pharmaceutical giant Dr Reddy Labs said in a release here.
In the initial weeks, the Company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India and with a subsidized rate offered to Government Institutions.
2-DG manufactured by Dr. Reddy’s has a purity of 99.5 per cent and is being sold commercially under the brand name 2DGTM.
2-DG, an oral drug, was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s.
It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care.
Emergency use approval for anti-COVID-19 therapeutic application of the drug was granted on May 1, 2021.